Phase II randomized trial of carboplatin and gemcitabine with or without dexamethasone pre-treatment in patients with Stage IV non-small cell lung cancer

Rinehart, John J.; Arnold, Susanne M.; Kloecker, Goetz; Lim, Allen; Zaydan, Muhammad Ali; Baeker, Thomas R.; Maheshwari, Jewraj G.; Carloss, Harry W.; Slone, Stacey; Shelton, Brent J.; Croley, J; Kvale, Elizabeth; Brooks, Michael; Leggas, Mark

doi:10.1007/s00280-013-2111-3

Cited by 17 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After screening titles and abstracts, 23 full-text articles were assessed for eligibility. Finally, a total of 12 articles met the inclusion criteria and were included in this meta-analysis (Forrest et al 2004 ; Leung et al 2012 ; Pinato et al 2014 ; Miyazaki et al 2015 ; Kishi et al 2015 ; Kawashima et al 2015 ; Jiang and Lu 2015 ; Grose et al 2015 ; Tomita et al 2014 ; MacKenzie et al 2014 ; Rinehart et al 2013 ; Meek et al 2010 ). Among these 12 articles, six were retrospective, and six were prospective studies.…”

Section: Resultsmentioning

confidence: 99%

Glasgow prognostic score predicts prognosis of non-small cell lung cancer: a meta-analysis

Zhu

Chen

et al. 2016

SpringerPlus

View full text Add to dashboard Cite

ObjectiveGlasgow prognostic score (GPS), an inflammation-based scoring system, has been evaluated in various cancers. However, its clinical significance remains unclear in non-small cell lung cancer (NSCLC). Therefore, it is necessary to conduct a meta-analysis to explore the prognostic value of GPS in NSCLC patients.MethodsA quantitative meta-analysis was performed through a systematic search in PubMed, Web of Science, and the Cochrane Library. The pooled hazard ratios (HRs) of overall survival (OS) were calculated and compared.ResultsA total of 12 studies comprising 2669 patients were included in this meta-analysis. Compared with GPS 0 group, patients in GPS 1–2 group exhibited a reduced OS with a pooled HR of 1.89 (95 % CI 1.57–2.27, p < 0.001; I2 = 54 %). Six studies had sufficient data to calculate HRs of OS for GPS 1 and GPS 2 groups. Analysis revealed that GPS 2 group had a statistically significant reduced OS compared with GPS 1 group with a pooled HR of 1.87 (95 % CI 1.18–2.97, p = 0.008; I2 = 72 %). Study type (retrospective vs. prospective) and disease stage could partially explain the heterogeneity of each study by subgroup analysis.ConclusionPretreatment GPS could serve as a simple and reliable prognosis predictor for NSCLC. More well-designed studies that consider GPS as a stratification factor are warranted.

show abstract

Section: Resultsmentioning

confidence: 99%

Glasgow prognostic score predicts prognosis of non-small cell lung cancer: a meta-analysis

Zhu

Chen

et al. 2016

SpringerPlus

View full text Add to dashboard Cite

show abstract

“…CRP, which is caused by microbial invasion and is synthesized by liver cells, is a reflection of local inflammation in the circulation (31). Its prognostic value in patients with various types of cancer was investigated in many studies (32)(33)(34)(35)(36)(37)(38). Furthermore, albumin can reflect the nutritional status of patients with cancer and malnutrition is correlated with worse survival (39).…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of the Glasgow prognostic score in lung cancer: evidence from 10 studies

Jin

Zhou

et al. 2017

Int J Biol Markers

View full text Add to dashboard Cite

show abstract

“…Dexamethasone treatment reduced haematological toxicity but had no effect on non-haematological toxicity or quality of life. Although the authors suggest that dexamethasone enhances the chemotherapeutic response, overall dexamethasone treatment did not significantly affect survival (Rinehart et al 2013).…”

Section: In Vivomentioning

confidence: 99%

Glucocorticoid receptors in lung cancer: new perspectives

Taylor

Ray

Sommer

2016

Journal of Endocrinology

View full text Add to dashboard Cite

Proper expression of the glucocorticoid receptor (GR) plays an essential role in the development of the lung. GR expression and signalling in the lung is manipulated by administration of synthetic glucocorticoids (Gcs) for the treatment of neonatal, childhood and adult lung diseases. In lung cancers, Gcs are also commonly used as co-treatment during chemotherapy. This review summarises the effect of Gc monotherapy and co-therapy on lung cancers in vitro, in mouse models of lung cancer, in xenograft, ex vivo and in vivo. The disparity between the effects of pre-clinical and in vivo Gc therapy is commented on in light of the recent discovery of GR as a novel tumour suppressor gene.

show abstract

Phase II randomized trial of carboplatin and gemcitabine with or without dexamethasone pre-treatment in patients with Stage IV non-small cell lung cancer

Abstract: Pre-treating patients with DEX is a safe, effective, and economic method of reducing the hematologic toxicity of carboplatin and gemcitabine. Our data suggest efficacy may also be enhanced by DEX pre-treatment.

Cited by 17 publications

References 24 publications

Glasgow prognostic score predicts prognosis of non-small cell lung cancer: a meta-analysis

Glasgow prognostic score predicts prognosis of non-small cell lung cancer: a meta-analysis

Prognostic value of the Glasgow prognostic score in lung cancer: evidence from 10 studies

Glucocorticoid receptors in lung cancer: new perspectives

Contact Info

Product

Resources

About